Novartis has been an outperformer since the beginning of this year, gaining about 15% in value. Novartis AG (ADR) ( NYSE :NVS) Alcon division also posted a growth in the second quarter. Analysts believe that Entresto has a huge potential in Europe, where the heart disease market is rising and will reach a worth of over $16 billion in the next ten years.
The street is also expecting Cosentyx sales to grow in the latest part of 2017. Novartis is expected to get an approval from FDA for its blood cancer therapy treatment, CAR-T therapy, in October.
Over the current book year the total revenue will be 48,61 billion CHF (consensus estimates). This is slightly lower than 2016's revenue of 49,39 billion CHF.
The analysts expect for 2017 a net profit of 10,99 billion CHF. The majority of the analysts expects for this year a profit per share of 4,75 CHF. So the price/earnings-ratio equals 17,35.
ValueSpectrum.com News Wire & Equity Research: +31 084-0032-842
Copyright analist.nl B.V.
All rights reserved. Any redistribution, duplication or archiving prohibited. analist.nl doesn't warrant the accuracy of any News Content provided and shall not be liable for any errors, inaccuracies or for any actions taken in reliance thereon.